for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Novavax to explore combined influenza/COVID-19 vaccine for use post pandemic

Oct 13 (Reuters) - Novavax Inc said on Tuesday it has set up a team of company veterans as it seeks U.S. regulatory approval for its seasonal influenza vaccine and to help develop a combined influenza/COVID-19 vaccine for use after the pandemic.

The flu vaccine, NanoFlu, met the primary and secondary goals in late-stage comparison study with Sanofi’s influenza vaccine Fluzone Quadrivalent earlier in the year.

Novavax is among global drugmakers racing to develop a vaccine for COVID-19 and last month started a late-stage trial of its experimental vaccine, NVX-CoV2373, in the United Kingdom.

NVX-CoV2373 is also being tested in two ongoing mid-stage trials that began in August.

Reporting By Mrinalika Roy in Bengaluru; Editing by Sriraj Kalluvila

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up